Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis

פריטים דומים

• Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
  מאת: Nishimoto, N, et al.
  יצא לאור: (2009)
• Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
  מאת: Nishimoto, Norihiro, et al.
  יצא לאור: (2008)
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL‐6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader‐blinded randomised controlled trial of tocilizumab
  מאת: Nishimoto, Norihiro, et al.
  יצא לאור: (2007)
• IL-15 and its role in rheumatoid arthritis
  מאת: Kurowska-Stolarska, M, et al.
  יצא לאור: (2003)
• Analysis of IL-10 gene variants in rheumatoid arthritis
  מאת: Huizinga, T, et al.
  יצא לאור: (2003)